HER2 inhibitors

Pertuzumab - Trastuzumab - Trastuzumab emtansine      

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

advanced breast cancer (metastatic)

pertuzumab
CLEOPATRA, 2012pertuzumab + trastuzumab +docetaxeltrastuzumab + docetaxel 1st line HER-2 positive NCT00567190Low risk of bias suggesting
neoSphere (Group B), 2012pertuzumab + trastuzumab +docetaxeltrastuzumab + docetaxel HER-2 positive NCT00545688Exploratory -
trastuzumab
TAnDEM (Kaufman), 2009trastuzumab + anastrozoleanastrozole alone HER-2 positive HR positive -
von Minckwitz, 2009trastuzumab + capecitabinecapecitabine alone HER-2 positive previously treated by HER-2 antibody trastuzumab failure -
Marty, 2005trastuzumab + docetaxeldocetaxel alone 1st line HER-2 positive M77001 -
Blackwell, 2010trastuzumab + lapatiniblapatinib alone ErbB2 positive previously treated by HER-2 antibody trastuzumab failure -
Huober, 2012trastuzumab + letrozoleletrozole alone HER-2 positive HR positive -
Gasparini, 2006trastuzumab + paclitaxelpaclitaxel alone HER-2 positive -
Slamon, 2001trastuzumab + standard chemotherapystandard chemotherapy alone HER-2 positive -
trastuzumab emtansine
EMILIA, 2012trastuzumab emtansinelapatinib plus capecitabine 2nd line HER-2 positive previously treated by HER-2 antibody previously treated by taxanes NCT00829166suggesting
TH3RESA, 2014trastuzumab emtansineusual care 2nd+ line HER-2 positive previously treated by HER-2 antibody NCT01419197Risk of bias suggesting

early breast cancer

pertuzumab
AphinitypertuzumabplaceboNCT01358877 -
trastuzumab
NSABP B31, 2005trastuzumabcontrolsuggesting
BCIRG006, 2013trastuzumabcontrolsuggesting
Buzdar, 2005trastuzumabcontrolsuggesting
FinHer, 2006trastuzumabcontrolnegative
HERA, 2005trastuzumabcontrolsuggesting
N9831, 2005trastuzumabcontrolsuggesting
NOAH, 2010trastuzumabcontrolnegative
PACS-04, 2009trastuzumabcontrolsuggesting
N9831 (1)trastuzumabcontrolsuggesting
N9831 (2)trastuzumabcontrolsuggesting
FinHer (1)trastuzumabcontrolnegative